


AMENDMENTS TO THE CLAIMS

1. (original) An 8-oxoadenine compound shown by the formula (1):



wherein ring A represents a 6-10 membered aromatic carbocyclic ring or a 5-10 membered heteroaromatic ring;

R represents a halogen atom, an alkyl group, a hydroxyalkyl group, a haloalkyl group, an alkoxy group, a hydroxyalkoxy group, a haloalkoxy group, amino group, an alkylamino group, a dialkylamino group, or a cyclic amino group;

n represents an integer of 0-2, and when n is 2, the Rs may be the same or different;

Z<sup>1</sup> represents a substituted or unsubstituted alkylene group or a substituted or unsubstituted cycloalkylene group;

X<sup>2</sup> represents oxygen atom, sulfur atom, SO<sub>2</sub>, NR<sup>5</sup>, CO, CONR<sup>5</sup>, NR<sup>5</sup>CO, SO<sub>2</sub>NR<sup>5</sup>, NR<sup>5</sup>SO<sub>2</sub>, NR<sup>5</sup>CONR<sup>6</sup> or NR<sup>5</sup>CSNR<sup>6</sup> (in which R<sup>5</sup> and R<sup>6</sup> are each independently hydrogen atom, a substituted or unsubstituted alkyl group, and a substituted or unsubstituted cycloalkyl group);

Y<sup>1</sup>, Y<sup>2</sup> and Y<sup>3</sup> represent each independently a single bond or an alkylene group;

X<sup>1</sup> represents oxygen atom, sulfur atom, SO<sub>2</sub>, NR<sup>4</sup> (wherein R<sup>4</sup> is hydrogen atom or an alkyl group) or a single bond;

R<sup>2</sup> represents hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group or a substituted or unsubstituted cycloalkyl group; and

R<sup>1</sup> represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxy carbonyl group, a haloalkyl group, a haloalkoxy group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group or a substituted or unsubstituted cycloalkyl group, or its pharmaceutically acceptable salt.

2. (previously presented) The 8-oxoadenine compound according to claim 1, wherein ring A represents a 6-10 membered aromatic carbocyclic ring, or a 5-10 membered heteroaromatic ring containing 1-4 hetero atoms selected from 0-4 nitrogen atoms, 0-2 oxygen atoms and 0-2 sulfur atoms;

R represents a halogen atom, an alkyl group of 1-6 carbons, a hydroxyalkyl group of 1-6 carbons, a haloalkyl group of 1-6 carbons, an alkoxy group of 1-6 carbons, a hydroxyalkoxy group of 1-6 carbons, a haloalkoxy group of 1-6 carbons, amino group, an alkylamino group of 1-6 carbons, a dialkylamino group in which each alkyl moiety has 1-6 carbons, and a cyclic amino group;

n is an integer of 0-2, and when n is 2, Rs may be the same or different;

Z<sup>1</sup> represents an alkylene group of 1-6 carbons or a cycloalkylene group of 3-8 carbons, which is optionally substituted by hydroxy group;

X<sup>2</sup> represents oxygen atom, sulfur atom, SO<sub>2</sub>, NR<sup>5</sup>, CO, CONR<sup>5</sup>, NR<sup>5</sup>CO, SO<sub>2</sub>NR<sup>5</sup>, NR<sup>5</sup>SO<sub>2</sub>, NR<sup>5</sup>CONR<sup>6</sup> or NR<sup>5</sup>CSNR<sup>6</sup> (in which R<sup>5</sup> and R<sup>6</sup> are independently hydrogen atom, a substituted or unsubstituted alkyl group of 1-6 carbons, and a substituted or unsubstituted cycloalkyl group of 3-8 carbons, wherein the substituents of the alkyl group or cycloalkyl group are selected from a halogen atom, hydroxy group, an alkoxy group of 1-6 carbons, carboxy group, an alkoxy carbonyl group of 2-5 carbons, carbamoyl group, amino group, an alkylamino group of 1-6 carbons, a dialkylamino group in which each alkyl moiety has 1-6 carbons, a cyclic amino group, carboxy group and tetrazolyl group which may be substituted by an alkyl group of 1-6 carbons);

Y<sup>1</sup>, Y<sup>2</sup> and Y<sup>3</sup> represent each independently a single bond or an alkylene group of 1-6 carbons;

X<sup>1</sup> represents oxygen atom, sulfur atom, SO<sub>2</sub>, NR<sup>4</sup> (wherein R<sup>4</sup> represents hydrogen atom or an alkyl group) or a single bond;

R<sup>2</sup> represents a substituted or unsubstituted alkyl group of 1-6 carbons, a substituted or unsubstituted alkenyl group of 2-6 carbons, a substituted or unsubstituted alkynyl group of 2-6 carbons or a substituted or unsubstituted cycloalkyl group of 3-8 carbons (wherein the substituent in the alkyl group, alkenyl group and alkynyl group is selected from a halogen atom, hydroxy group, an alkoxy group of 1-6 carbons, an acyloxy group of 2-10 carbons, amino group,

an alkylamino group of 1-6 carbons, a dialkylamino group in which the each alkyl moiety has 1-6 carbons, and a cyclic amino group); and

R<sup>1</sup> represents hydrogen atom, hydroxy group, an alkoxy group of 1-6 carbons, an alkoxycarbonyl group of 2-5 carbons, a haloalkyl group of 1-6 carbons, a haloalkoxy group of 1-6 carbons, a substituted or unsubstituted aryl group of 6-10 carbons, a substituted or unsubstituted 5-10 membered heteroaryl group containing 1-4 hetero atoms selected from 0-4 nitrogen atoms, 0-2 oxygen atoms and 0-2 sulfur atoms, or a substituted or unsubstituted cycloalkyl group of 3-8 carbons;

and the said substituent in the aryl group, the heteroaryl group and the cycloalkyl group is selected from a halogen atom, hydroxy group, an alkyl group of 1-6 carbons, a haloalkyl group of 1-6 carbons, an alkoxy group of 1-6 carbons, a haloalkoxy group of 1-6 carbons, an alkylcarbonyl group of 2-5 carbons, amino group, an alkylamino group of 1-6 carbons and a dialkylamino group (wherein the each alkyl group has 1-6 carbons),

and the said cyclic amino group represents a 4-7 membered saturated cyclic amino group containing 1-2 hetero atoms selected from 1-2 nitrogen atoms, 0-1 oxygen atom and 0-1 sulfur atom, which may be substituted with a halogen atom, hydroxy group, oxo group, an alkyl group of 1-6 carbons, an alkoxy group of 1-6 carbons, an alkylcarbonyl group of 2-5 carbons or an alkoxycarbonyl group of 2-5 carbons,

or its pharmaceutically acceptable salt.

3. (previously presented) The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1 or 2, wherein X<sup>2</sup> is oxygen atom, sulfur atom, NR<sup>5</sup>, SO<sub>2</sub>, NR<sup>5</sup>SO<sub>2</sub> or NR<sup>5</sup>CONR<sup>6</sup>.

4. (previously presented) The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1, wherein Y<sup>3</sup> is a single bond, methylene or ethylene.


5. (previously presented) The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1, wherein Z<sup>1</sup> is a straight chained alkyelne group of 1-6 carbons which may be substituted with hydroxy group.

6. (previously presented) The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1, wherein X<sup>1</sup> is oxygen atom or sulfur atom.

7. (previously presented) The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1, wherein Y<sup>1</sup> is a single bond or an alkylene group of 1-6 carbons.


8. (previously presented) The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1, wherein R<sup>1</sup> is hydrogen atom, an alkoxy carbonyl group, hydroxy group, or an alkoxy group.

9. (previously presented) The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1, wherein a group shown by the formula (2) in the formula (1):




(wherein ring A, R, n, Y<sup>3</sup> and R<sup>2</sup> have the same meaning as in claim 1)

is a group shown by the formula (3) or the formula (4):



(3)




(4)

(wherein R, n and R<sup>2</sup> have the same meaning as in claim 1, and R<sup>3</sup> is hydrogen atom or an alkyl group).

10. (Original) The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 9, wherein R<sup>2</sup> is methyl group or an alkyl group of 2-6 carbons substituted by a dialkylamino group or a cyclic amino group.


11. (Original) The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 9 or 10, wherein R<sup>3</sup> is hydrogen atom.
  12. (previously presented) A pharmaceutical composition comprising the 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1 as an active ingredient.
  13. (previously presented) An composition comprising the 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1as an active ingredient, wherein said composition has immuno-modulatory activity.
  14. (previously presented) A composition comprising the 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1 as an active ingredient, wherein said composition has antiviral, anticancer or anti-allergy activity.
  15. (previously presented) A composition comprising the 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1 as an active ingredient, wherein said composition is formulated for topical administration.
- 16-18. (canceled)
19. (previously presented) A method for modulating immune response which comprises administering to a patient, an effective amount of the 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1.
  20. (previously presented) A method for treating or preventing viral diseases, cancers and allergic diseases which comprises administering to a patient, an effective amount of the 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1.
  21. (previously presented) A process for preparing the 8-oxoadenine compound according to claim 1 which comprises brominating a compound shown by the formula (10):



wherein ring A, n, R, R<sup>1</sup>, R<sup>2</sup>, X<sup>1</sup>, X<sup>2</sup>, Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Z<sup>1</sup> are the same defined in the claim 1,


reacting the resultant of the bromination with a metal alkoxide and then hydrolyzing, or hydrolyzing the resultant of the bromination.

22. (Original) A compound shown by the formula (10):




wherein ring A, n, R, R<sup>1</sup>, R<sup>2</sup>, X<sup>1</sup>, X<sup>2</sup>, Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Z<sup>1</sup> are the same defined in the claim 1.

23. (previously presented) A process for preparing the 8-oxoadenine compound according to claim 1 which comprises deprotecting a compound shown by the formula (11):



wherein ring A, n, R, R<sup>1</sup>, R<sup>2</sup>, X<sup>1</sup>, X<sup>2</sup>, Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Z<sup>1</sup> are the same defined in the claim 1.

24. (Original) A compound shown by the formula (11):



wherein ring A, n, R, R<sup>1</sup>, R<sup>2</sup>, X<sup>1</sup>, X<sup>2</sup>, Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Z<sup>1</sup> are the same defined in the claim 1.

25. (Previously presented) A compound or a pharmaceutically acceptable salt thereof selected from the group consisting of the following compounds:

- 2-Butoxy-8-oxo-9-[2-(3-methoxycarbonylphenoxy)ethyl]adenine,
- 2-Butoxy-8-oxo-9-[2-(3-methoxycarbonylmethylphenoxy)ethyl]adenine,
- 2-Butoxy-8-oxo-9-[2-(2-methoxycarbonylphenoxy)ethyl]adenine,
- 2-Butoxy-8-oxo-9-[2-(2-methoxycarbonylmethylphenoxy)ethyl]adenine,
- 2-Butoxy-8-oxo-9-[2-(4-methoxycarbonylphenoxy)ethyl]adenine,
- 2-Butoxy-8-oxo-9-[2-(4-methoxycarbonylmethylphenoxy)ethyl]adenine,

2-Butoxy-8-oxo-9-{2-[4-(2-methoxycarbonylethyl)phenoxy]ethyl}adenine,  
2-Butoxy-8-oxo-9-[4-(3-methoxycarbonylbenzenesulfonamide)butyl]adenine,  
2-Butoxy-8-oxo-9-[4-(3-methoxycarbonylmethylbenzenesulfonamide)butyl]adenine,  
2-Butoxy-8-oxo-9-[4-(3-methoxycarbonylphenylaminocarbonylamino)butyl]adenine,  
2-Butoxy-8-oxo-9-[4-(3-methoxycarbonylmethylphenylaminocarbonylamino)butyl]adenine,  
Methyl [3-({[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)ethyl]amino}methyl)phenyl]acetate,  
[3-({[2-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)ethyl]amino}methyl)phenyl]acetic acid,  
Methyl 3-({[3-(6-mino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl]amino}methyl)benzoate,  
3-({[3-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl]amino}methyl)benzoic acid,  
Methyl 4-({[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl]amino}methyl)benzoate,  
4-({[3-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl]amino}methyl)benzoic acid,  
Methyl (3-{{[3-(6-amino-2-butoxy-8-oxo-9H-purin-9-yl)propyl](2-morpholin-4-ylethyl)amino}methyl}phenyl)acetate,  
Methyl [3-({[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl]amino}methyl)phenyl]acetate,  
Ethyl 2-[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)ethoxy]benzoate,  
3-(Dimethylamino)propyl 2-[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)ethoxy]benzoate,  
Methyl 3-[4-({[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl]amino}sulfonyl)phenyl]propanoate,  
3-[4-({[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl]amino}sulfonyl)phenyl]propanoic acid,  
Methyl (3-{{[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl](2-pyrrolidin-1-ylethyl)amino}sulfonyl}phenyl)acetate,  
(3-{{[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl](2-pyrrolidin-1-ylethyl)amino}sulfonyl}phenyl)acetic acid,

Methyl (3-{{[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl](2-methoxyethyl)amino]sulfonyl}phenyl)acetate,  
(3-{{[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl](2-methoxyethyl)amino]sulfonyl}phenyl)acetic acid,  
Methyl (3-{{[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl](methyl)amino]sulfonyl}phenyl)acetate,  
(3-{{[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl](methyl)amino]sulfonyl}phenyl)acetic acid,  
Methyl [3-({[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl][3-(dimethylamino)-2,2-dimethylpropyl]amino}sulfonyl)phenyl]acetate,  
[3-({[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl][3-(dimethylamino)-2,2-dimethylpropyl]amino}sulfonyl)phenyl]acetic acid,  
Methyl [3-({[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl]amino}sulfonyl)phenyl]acetate,  
Methyl (3-{{[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl](2-hydroxy-2-methylpropyl)amino]sulfonyl}phenyl)acetate,  
(3-{{[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl](2-hydroxy-2-methylpropyl)amino]sulfonyl}phenyl)acetic acid,  
Methyl [3-({[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)ethyl]amino}sulfonyl)phenyl]acetate,  
Methyl [3-({[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl][(2R)-2,3-dihydroxypropyl]amino}sulfonyl)phenyl]acetate,  
[3-({[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl][(2R)-2,3-dihydroxypropyl]amino}sulfonyl)phenyl]acetic acid,  
Methyl 3-({[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl][3-(dimethylamino)-2,2-dimethylpropyl]amino}sulfonyl)benzoate,  
3-({[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl][3-(dimethylamino)-2,2-dimethylpropyl]amino}sulfonyl)benzoic acid,  
Methyl (3-{{[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate,

(3-{{{4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl}(3-morpholin-4-ylpropyl)amino}methyl}phenyl)acetic acid,

Methyl [3-({{4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl}[3-(dimethylamino)-2,2-dimethylpropyl]amino}methyl)phenyl]acetate,

[3-({{4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl}[3-(dimethylamino)-2,2-dimethylpropyl]amino}methyl)phenyl]acetic acid,

Methyl [3-({{4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl}[3-(2-oxopyrrolidin-1-yl)propyl]amino}methyl)phenyl]acetate,

[3-({{4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl}[3-(2-oxopyrrolidin-1-yl)propyl]amino}methyl)phenyl]acetic acid,

Methyl (3-{{{4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl}(2-morpholin-4-ylethyl)amino}methyl}phenyl)acetate,

(3-{{{4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl}(2-morpholin-4-ylethyl)amino}methyl}phenyl)acetic acid,

Methyl (3-{{{3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl}(3-morpholin-4-ylpropyl)amino}methyl}phenyl)acetate,

Methyl [3-({{4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl}[2-(1H-tetrazol-5-yl)ethyl]amino}methyl)phenyl]acetate,

Methyl (3-{{{2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)ethyl}thio}phenyl)acetate,

(3-{{{2-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)ethyl}thio}phenyl)acetic acid,

Methyl (3-{{{2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)ethyl}amino}phenyl)acetate,

Methyl (3-{{{3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl}amino}phenyl)acetate,

(3-{{{3-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl}amino}phenyl)acetic acid,

Methyl [3-({{3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl}amino}methyl)phenyl]acetate,

([3-({{3-(6-Amino-2-butoxy-8-methoxy-9H-purin-9-yl)propyl}amino}methyl)phenyl]acetic acid,

Methyl (3-{{{2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)ethyl}(2-

methoxyethyl)amino]methyl}phenyl)acetate,  
(3-{[[2-(6-Amino-2-butoxy-8-methoxy-9H-purin-9-yl)ethyl](2-methoxyethyl)amino]methyl}phenyl)acetic acid,  
Methyl (3-{[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)ethyl]sulfonyl}phenyl)acetate,  
Methyl (3-{[[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)ethyl](methyl)amino]methyl}phenyl)acetate,  
(3-{[[2-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)ethyl](methyl)amino]methyl}phenyl)acetic acid,  
Methyl 4-[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)-2-hydroxypropoxy]benzoate,  
Methyl (3-{[[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)ethyl](2-hydroxyethyl)amino]methyl}phenyl)acetate,  
Methyl (3-{[[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl](2-hydroxyethyl)amino]methyl}phenyl)acetate,  
2-Butoxy-8-oxo-9-[2-(3-hydroxycarbonylphenoxy)ethyl]adenine,  
2-Butoxy-8-oxo-9-[2-(3-hydroxycarbonylmethylphenoxy)ethyl]adenine,  
2-Butoxy-8-oxo-9-[2-(2-hydroxycarbonylphenoxy)ethyl]adenine,  
2-Butoxy-8-oxo-9-[2-(2-hydroxycarbonylmethylphenoxy)ethyl]adenine,  
2-Butoxy-8-oxo-9-[2-(4-hydroxycarbonylphenoxy)ethyl]adenine,  
2-Butoxy-8-oxo-9-[2-(4-hydroxycarbonylmethylphenoxy)ethyl]adenine,  
2-Butoxy-8-oxo-9-{2-[4-(2-hydroxycarbonylethyl)phenoxy]ethyl}adenine,  
2-Butoxy-8-oxo-9-[4-(3-hydroxycarbonylbenzenesulfonamide)butyl]adenine,  
2-Butoxy-8-oxo-9-[4-(3-hydroxycarbonylmethylbenzenesulfonamide)butyl]adenine,  
2-Butoxy-8-oxo-9-[4-(3-hydroxycarbonylphenylaminocarbonylamino)butyl]adenine and  
2-Butoxy-8-oxo-9-[4-(3-hydroxycarbonylmethylphenylaminocarbonylamino)butyl]adenine.

26. (New) Methyl (3-{[[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate or a pharmaceutically acceptable salt thereof.

27. (New) Methyl (3-{[[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl][3-(dimethylamino)-2,2-dimethylpropyl]amino]methyl}phenyl)acetate or a pharmaceutically acceptable salt thereof.
28. (New) Methyl (3-{[[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl](2-morpholin-4-ylethyl)amino]methyl}phenyl)acetate or a pharmaceutically acceptable salt thereof.
29. (New) Methyl (3-{[[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate or a pharmaceutically acceptable salt thereof.
30. (New) Methyl (3-{[[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl](2-hydroxyethyl)amino]methyl}phenyl)acetate or a pharmaceutically acceptable salt thereof.